Obexelimab Biosimilar - Research Grade

Human

CD19ï؟½

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P15391;P15391;P25918;P51677

Blue ice

CD19 is a B-cell-restricted co-receptor and a heavily studied target in B-cell malignancy and autoimmunity research. Modeled on obexelimab, this unconjugated, non-therapeutic human IgG1 kappa antibody is expressed in CHO cells against human CD19. Provided for research use only, it is purified to a low-endotoxin grade suitable for in vivo studies and offered in scalable milligram (mg) to gram (g) batches for high-throughput and heavy-usage programs. It serves as a dependable reagent for B-cell phenotyping, functional signaling assays, in vivo immunology models, and antibody-engineering workflows. Tight quality control makes it a steady reagent for high-throughput pipelines.

RB4v1.2 ;B lymphocyte surface antigen B4, Leu-12

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks